Trade now with Barclays Stockbrokers
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
30-Jan-25 |
Buy |
Carolyn Cross |
12.00p | 200,775 |
£24,093.00 |
03-Feb-25 |
Buy |
Carolyn Cross |
12.50p | 149,225 |
£18,653.13 |
31-Jan-25 |
Buy |
Carolyn Cross |
12.50p | 100,000 |
£12,500.00 |
05-Feb-25 |
Buy |
Nicolas Loebel |
12.60p | 25,000 |
£3,150.00 |
Carolyn Cross |
156,314,029 |
£25,401,030 |
Nicolas Loebel |
3,538,991 |
£575,086 |
Junaid Bajwa |
1,193,697 |
£193,976 |
Jean Duvall |
1,163,529 |
£189,074 |
Jean Charest |
353,356 |
£57,420 |
Simon Sinclair |
256,327 |
£41,653 |
Carolyn Cross |
118,091,377 |
£19,189,849 |
M&G Plc |
40,588,235 |
£6,595,588 |
Robert Cross |
25,858,400 |
£4,201,990 |
Albemarle Life Sciences Fund |
15,105,882 |
£2,454,706 |
CRUX Asset Management |
9,298,090 |
£1,510,940 |
Chelverton Asset Management |
7,957,311 |
£1,293,063 |
15:40 |
125,000 @ 14.70p |
16:28 |
50,000 @ 16.45p |
16:19 |
50,000 @ 16.40p |
16:24 |
10,000 @ 16.11p |
16:19 |
5,152 @ 16.50p |
Chair |
Jean Charest |
CEO |
Carolyn Cross |
Top of Page
You are here:
research